Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical study. The new approach, which requires further development and testing, could someday enable the much wider use of islet transplants to cure diabetes.
Tag: Transplantation and Transplant Rejection
Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia
Abstract Background The BCR::ABL1 tyrosine kinase inhibitors (TKIs) have significantly improved the outcomes of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). However, the optimal duration of TKI therapy in patients who achieve a complete molecular response (CMR; undetectable BCR::ABL1 transcripts) and who do not undergo allogeneic stem cell transplantation (allo-SCT) remains undefined. Methods… Continue reading Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia
Adulthood outcomes of thymic transplantation in a case of congenital athymia due to FOXN1 mutation
Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study
Abstract Background The GOSSAMER phase 2 study assessed the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib as maintenance therapy in patients with FLT3–internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML) in first complete remission without previous hematopoietic stem cell transplantation (HSCT). Methods Patients had to be within 2 months of their last consolidation cycle and… Continue reading Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study
Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study
Abstract Background The GOSSAMER phase 2 study assessed the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib as maintenance therapy in patients with FLT3–internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML) in first complete remission without previous hematopoietic stem cell transplantation (HSCT). Methods Patients had to be within 2 months of their last consolidation cycle and… Continue reading Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study
Acetyltransferase NAT10 inhibits T-cell immunity and promotes nasopharyngeal carcinoma progression through DDX5/HMGB1 axis
Background Immunosuppression significantly contributes to treatment failure in nasopharyngeal carcinoma (NPC). Messenger RNA (mRNA) modifications such as methylation and acetylation play crucial roles in immunosuppression. However, N4-acetylcytidine (ac4C), the only acetylation modification event has rarely been studied in NPC. Methods First, clinical tissue samples and nude mouse models were used to explore the expression of… Continue reading Acetyltransferase NAT10 inhibits T-cell immunity and promotes nasopharyngeal carcinoma progression through DDX5/HMGB1 axis
Novel MSC-based therapy provides hope for ocular GVHD treatment
Graft-versus-host disease (GVHD) is a common and severe complication that occurs after stem cell transplantation, where the donor’s immune cells attack the recipient’s tissues. Ocular manifestation of GVHD is among the most challenging to treat, often leading to chronic inflammation and corneal tissue damage, which can result in loss of vision. Conventional treatments, including corticosteroids,… Continue reading Novel MSC-based therapy provides hope for ocular GVHD treatment
European Myeloma Network Group Review and Consensus Statement on Primary Plasma Cell Leukemia
Primary plasma cell leukemia (PPCL) is the most aggressive disorder among plasma cell malignancies, with new diagnostic criteria recently established by the International Myeloma Working Group. Studies have shown that PPCL patients receiving a combination of novel agents, but not eligible for transplantation, may have a median survival up to 2 years, extended to 3… Continue reading European Myeloma Network Group Review and Consensus Statement on Primary Plasma Cell Leukemia